Skip to main content
Erschienen in: Drugs 14/2020

Open Access 01.09.2020 | Correction

Correction to: Satralizumab: First Approval

verfasst von: Young-A Heo

Erschienen in: Drugs | Ausgabe 14/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1007/​s40265-020-01380-2.

1 Correction to: Drugs https://​doi.​org/​10.​1007/​s40265-020-01380-2

The article Satralizumab: First Approval, written by Young-A Heo, was originally published electronically in SpringerLink on 14 August 2020 without open access. After publication F. Hoffmann-La Roche AG, requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by F. Hoffmann-La Roche AG. This article is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit https://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.
The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt bestellen und 100 € sparen!

e.Dent – Das Online-Abo der Zahnmedizin

Online-Abonnement

Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

Metadaten
Titel
Correction to: Satralizumab: First Approval
verfasst von
Young-A Heo
Publikationsdatum
01.09.2020
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 14/2020
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01391-z

Weitere Artikel der Ausgabe 14/2020

Drugs 14/2020 Zur Ausgabe